echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA Committee of Experts Opposes Approval of Roxastat

    FDA Committee of Experts Opposes Approval of Roxastat

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text | pick up shells

    On July 15, the US FDA Cardiovascular and Renal Drug Advisory Committee (CRDAC) voted against the approval of the oral HIF-PH inhibitor Roxadustat (Roxadustat) developed by Fabojin/AstraZeneca for the treatment of patients with chronic kidney disease and anemia.


    Roxastat is an oral firsit-in-class small molecule hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which can increase the production of endogenous erythropoietin and improve iron absorption And mobilize and down-regulate hepcidin to promote erythropoiesis


    The expert committee opposed the approval of roxastat for the treatment of chronic kidney disease anemia in non-dialysis patients, mainly because of concerns about the overall situation of the safety data, and they expressed their concern about the post-marketing study proposed by the partner (AstraZeneca) to understand more Many proposals regarding the drug's cardiac safety are doubtful


    The only person who voted for it was Dr.


    For CKD patients on dialysis, the expert committee voted against approval with a vote of 2:12


    During the meeting, the panel members of the FDA Cardiovascular and Renal Medicine Advisory Committee discussed the safety and effectiveness of the drug in dialysis and non-dialysis patients, as well as the registration criteria for clinical research projects, and a potential post-marketing study


    Most of the discussion focused on the safety of use by medical institutions and the application materials submitted by the company


    At a public hearing before the vote, patients and doctors asked experts to support the drug's listing, citing the challenges of current treatments and the advantages of oral drugs


    New York City nephrologist Dr.


    The result of the vote of the FDA Expert Advisory Committee has greatly increased the risk of uncertainty in FDA's approval of the drug


    For rosarestat, the FDA's initial PDUFA deadline was December 2020, but the agency later extended its review to March 2021


    After experiencing successive delays, the partners encountered another setback in April.


    The industry view personnel initially considered the drug to be a blockbuster because they believed that it could seize market share from the standard therapy recombinant human erythropoietin and also gain additional market share from non-dialysis patients


    Roxastat has been approved in China, Japan, Chile and South Korea for the treatment of chronic renal anemia in non-dialysis dependent (NDD) and dialysis dependent (DD) adults


    Astellas and FibroGen are jointly responsible for the development and commercialization of Roxastat in Japan, Europe, Turkey, Russia, the Commonwealth of Independent States, the Middle East and South Africa


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.